ID | 60796 |
JaLCDOI | |
FullText URL | |
Author |
Makimoto, Go
Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center
Ohashi, Kadoaki
Department of Respiratory Medicine, Okayama University Hospital
ORCID
Kaken ID
researchmap
Maeda, Yoshinobu
Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kaken ID
researchmap
Kiura, Katsuyuki
Department of Respiratory Medicine, Okayama University Hospital
ORCID
Kaken ID
publons
researchmap
|
Abstract | The prognosis of advanced non-small cell lung cancer (NSCLC) patients has improved in recent decades, especially for patients with an oncogenic driver mutation. Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are effective for patients with the echinoderm microtubule-associated protein-like 4-ALK fusion gene. Several ALK-TKIs have been established: the first-generation ALK-TKI, crizotinib; second-generation ALK-TKIs, alectinib and ceritinib; and third-generation ALK-TKI, lorlatinib. Some ALK-TKIs are effective for tumors that are resistant to other ALK-TKIs; however, as is known in epidermal growth factor receptormutant lung cancer, tumor resistance is inevitable. ALK-positive NSCLCs acquire resistance via various mechanisms, making it a heterogeneous disease. Therefore, it is necessary to develop next-generation treatment strategies, such as the use of next-generation ALK-TKIs for secondary mutations, or combination therapies with ALK-TKIs and other TKIs. In this review, we summarize the development and use of ALK-TKIs, prior pivotal clinical trials, and resistance mechanisms.
|
Keywords | lung cancer
anaplastic lymphoma kinase
tyrosine kinase inhibitors
resistance mechanism
|
Amo Type | Review
|
Publication Title |
Acta Medica Okayama
|
Published Date | 2020-10
|
Volume | volume74
|
Issue | issue5
|
Publisher | Okayama University Medical School
|
Start Page | 371
|
End Page | 379
|
ISSN | 0386-300X
|
NCID | AA00508441
|
Content Type |
Journal Article
|
language |
English
|
Copyright Holders | CopyrightⒸ 2020 by Okayama University Medical School
|
File Version | publisher
|
Refereed |
True
|
PubMed ID | |
Web of Science KeyUT | |
NAID |